Annals of Oncology Acceptance Rate

There is no stable official acceptance-rate figure from the journal or publisher that is strong enough to anchor this query around exact precision.

What is stable is the editorial model:

• the journal is highly selective about clinical consequence
• randomized trials, guideline-relevant datasets, and treatment-shaping evidence matter most
• translational work usually needs a clear bridge to patient care
• the ESMO flagship identity raises the bar on evidence maturity and relevance

That is the planning surface authors actually need.

Annals of Oncology is usually asking:

• will this change clinical interpretation, treatment choice, or guideline-level thinking?
• is the evidence mature enough to support that consequence?
• does the paper belong in a broad oncology flagship rather than a narrower specialty title?
• is the translational or biomarker work tied tightly enough to real patient meaning?

Those are the questions that matter more than a rumored percentage.

For Annals of Oncology, the useful question is:

If this paper is true, does it have enough broad oncology consequence to matter at ESMO-flagship level?

If yes, the journal is plausible. If no, the acceptance-rate discussion is mostly noise.

The common misses are:

• centering strategy around an unofficial percentage
• treating strong oncology science as automatically broad clinical fit
• overestimating what early-phase or lightly validated biomarker work can do here
• confusing society prestige with a destination for any good cancer paper

Those are fit problems before they are rate problems.

If you are deciding whether to submit, these pages are more useful than an unofficial rate:

• is Annals of Oncology a good journal
• JAMA Oncology
• Journal of Clinical Oncology
• how to choose a journal for your paper

Together, they tell you whether the paper is broad enough for a flagship oncology readership, whether another top oncology venue is cleaner, and whether the manuscript really deserves this tier.

In our pre-submission review work evaluating manuscripts targeting Annals of Oncology, three patterns generate the most consistent desk rejections. Each reflects the ESMO flagship journal's documented editorial focus on evidence maturity and clinical consequence.

Early-phase efficacy data without translational patient-selection signal. Annals of Oncology's editorial focus on clinical consequence means that Phase I and Phase II efficacy data requires a particularly strong translational rationale to clear the desk. A Phase I dose-escalation study showing safety and preliminary efficacy with response rates in single digits is not Annals of Oncology material regardless of the target's novelty. The ESMO readership expects that first-in-human and early-phase data is accompanied by biomarker hypotheses or molecular stratification approaches that would define which patients benefit. Papers that report efficacy without a patient-selection framework are returned with a note that the evidence maturity does not meet the journal's standard for broad clinical relevance.

Single-tumor biomarker findings without pathway-level generalizability. Annals of Oncology has a strong tradition of publishing biomarker and translational studies, but the journal expects those studies to connect to broader oncology questions. A study identifying a biomarker in colorectal cancer that is specific to that tumor type, not connected to a shared oncogenic pathway, and not validated in independent cohorts faces a high desk rejection rate. The editorial question is whether a clinician treating breast cancer or lung cancer would update their understanding of biomarker-driven treatment by reading this study. Papers that answer yes for a broad oncology readership have substantially better odds than papers that answer yes only for colorectal cancer specialists.

Practice implications stated rather than demonstrated. Many manuscripts submitted to Annals of Oncology claim practice-changing significance in the abstract without the evidence to support it. The specific failure is framing early or exploratory findings as "changing clinical practice" or "establishing a new standard of care" when the study design, sample size, or endpoint does not support that conclusion. ESMO reviewers are oncologists with deep clinical experience, and language that overstates clinical consequence without proportionate evidence damages credibility before review even begins. The abstract should make the strongest defensible claim, not the most ambitious one. A Annals of Oncology submission readiness check can assess whether the clinical significance framing matches the evidence maturity and meets the Annals of Oncology standard before submission.

The honest answer to "what is the Annals of Oncology acceptance rate?" is that there is no strong official number you should treat as exact.

The useful answer is:

• yes, the journal is highly selective
• no, a guessed percentage is not the right planning tool
• use clinical consequence, evidence maturity, and broad oncology relevance instead

If you want help pressure-testing whether the paper is really broad enough for this tier before submission, a Annals of Oncology submission readiness check is the best next step.

The acceptance rate at Annals of Oncology is only one dimension of selectivity. What matters more is where in the process papers are filtered. Most rejections at selective journals happen at the desk - the editor reads the abstract, cover letter, and first few paragraphs and decides whether to send the paper for external review. Papers that make it past the desk have substantially better odds.

For authors, this means the real question is not "what percentage of papers get accepted?" but "will my paper survive the desk screen?" The desk screen is about scope fit, novelty signal, and evidence maturity - not about statistical odds.

If you are considering Annals of Oncology, these specific steps improve your chances:

• Lead with the advance, not the method. The first paragraph of your abstract should state what changed in the field, not how you ran the experiment.

• Match the journal's scope precisely. Read the last 3 issues. If your paper's topic doesn't appear, the desk rejection risk is high.

• Include a cover letter that addresses fit. Name the specific reason this paper belongs at Annals of Oncology rather than a competitor.

• Ensure the data package is complete. Missing controls, weak statistics, or incomplete characterization are common desk-rejection triggers.

• Check formatting requirements. Trivial formatting errors signal carelessness to editors.

For Annals of Oncology, authors should expect:

These are approximate ranges. Actual timelines vary by manuscript complexity, reviewer availability, and whether revisions are needed.

The acceptance rate for Annals of Oncology does not distinguish between desk rejections and post-review rejections. A paper desk-rejected in 2 weeks and a paper rejected after 4 months of review both count the same. The rate also does not reveal how acceptance varies by article type, geographic origin, or research area within the journal's scope.

Acceptance rates cannot predict your individual odds. A strong paper with clear scope fit, complete data, and solid methodology has substantially better odds than the headline number suggests. A weak paper with methodology gaps will be rejected regardless of the journal's overall rate.

A Annals of Oncology submission readiness check identifies the specific framing and scope issues that trigger desk rejection before you submit.